Добавить новость
ru24.net
News in English
Декабрь
2022

Новости за 27.12.2022

COVID-19 vs Influenza for Risk of Thrombotic Events in Hospitalized Patients

Jamanetwork.com 

To the Editor We have several concerns about the recent study that demonstrated that hospitalization with COVID-19 before and during COVID-19 vaccine availability vs hospitalization with influenza in 2018-2019 was significantly associated with a higher risk of venous thromboembolism within 90 days.

A Plea For the Development of Pathology

Jamanetwork.com 

Pathology, in its early development, was a by-product of anatomy during that period when the first dissections of the human body were developing anatomic knowledge. Morgagni, Vesalius, Fallopius, Eustachius, and others of the earlier anatomists, whose names are still attached to hydatids, tubes and various other structures of the body, made note of abnormalities encountered in the course of their anatomic investigations. Pathology, during this early stage of its development, could not be considered... Читать дальше...

HHS Releases New Report on Long COVID Experiences

Jamanetwork.com 

The US Department of Health and Human Services (HHS) published a report highlighting the experiences of patients with long COVID. Between 5% and 30% of people who had COVID-19 may develop long COVID conditions, and about 1 million individuals aren’t in the workforce “at any given time” because of related symptoms, according to an HHS statement. It also notes that researchers have documented more than 50 long COVID conditions that affect nearly all organ systems.

VA Finds Nirmatrelvir Associated With Lower Risk of Long Covid

Jamanetwork.com 

The antiviral therapy nirmatrelvir, 1 of the medications used in Paxlovid, may mitigate the development of long COVID conditions, according to an observational study by the US Department of Veterans Affairs (VA). The study was posted to the preprint server medRxiv in early November and had not yet been peer-reviewed.

Restoring Physician Authority in an Era of Hospital Dominance

Jamanetwork.com 

In this issue of JAMA, Ahmed et al report that approximately 1 in 10 health care workers are union members and that union membership is associated with higher wages, better benefits, and more equitable compensation across races and ethnicities. This analysis opens a new and timely avenue of research into the impact of unionization on the health care workforce.



The Relationship Between Income and Child Health

Jamanetwork.com 

Researchers have been using statistical methods to investigate the link between health and income in both adults and children since individual-level data allowing them to do so first became available. However, previous investigators were forced to rely on highly imperfect data. Sample sizes were often small, indicators for socioeconomic status were crude, and health status and the presence or absence of acute and chronic conditions was generally self (or parent) reported. Despite these limitations... Читать дальше...

Graphic Medicine—The Best of 2022

Jamanetwork.com 

This Arts and Medicine feature reviews 2 books published in 2022: a clinical ethics graphic medicine casebook illustrating how ethical dilemmas in clinical practice play out in real situations; and a graphic public health comics anthology showing how comics meet the needs of risk communication and health promotion.

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares. NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer NANOBIOTIX announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy. Harm Reduction Therapeutics' New Drug Application for RiVive™ Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA 12/26/2022 Harm Reduction Therapeutics, Inc., a 501 nonprofit pharmaceutical company whose mission is to prevent opioid overdose deaths by making free or low-cost over-the-counter naloxone nasal spray available to the public, announced that the FDA has accepted its New Drug Application for OTC RiVive for the emergency treatment of opioid overdose. Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies 12/26/2022 Ablaze Pharmaceuticals announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. to develop series of targeted radiopharmaceutical therapy products. Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region 12/26/2022 Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, for toripalimab in the Middle East and North Africa. Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine 12/26/2022 Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines. Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca 12/26/2022 Lightnix Inc. has decided to participate as a partner company in "Innovation Infusion Japan”, an initiative sponsored by AstraZeneca K.K. i2.JP is a new initiative that promotes open innovations in the healthcare field. Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) 12/25/2022 Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced that the companies have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma by the Prescription Drug User Fee Action date of December 23, 2022. Arcus Biosciences Announces New Employment Inducement Grants - December 24, 2022 12/24/2022 Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,250 shares of the Company’s common stock at an exercise price per share of $20.41, which was the closing price on December 23, 2022, and restricted stock units to acquire a total of 5,625 shares of the Company’s common stock. Pulnovo Medical will be attending JPM Healthcare Conference 2023 12/24/2022 Pulnovo Medical Limited, a globally recognized OTM innovative platform, will be attending the upcoming 41st J.P. Morgan Healthcare Conference 2023 to discuss the latest trends in innovative technologies and development strategies in the medical device sector with global peers. Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) 12/24/2022

Feedity.com 

Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.

Новости России
Москва

Роскошь Москва-Сити поразила туриста из Германии: такси и смотровая оказались не по карману



Спорт в России и мире

Новости спорта


Новости тенниса
WTA

Эрика Андреева проиграла пятый матч подряд, уступив в 1-м круге турнира WTA-125 в Париже






Юрист рассказал, в каких случаях загранспорт оформят за три дня

Москва попала в рейтинг самых популярных российских направлений для отдыха летом

Строители приступили к отделочным работам в ходе капремонта лицея № 23 в Белоозерском

Советский Союз согласился вывести войска из Австрии 70 лет назад